Contrasting AXIM Biotechnologies (OTCMKTS:AXIM) and Icosavax (NASDAQ:ICVX)

Icosavax (NASDAQ:ICVXGet Free Report) and AXIM Biotechnologies (OTCMKTS:AXIMGet Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Earnings and Valuation

This table compares Icosavax and AXIM Biotechnologies’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Icosavax $580,000.00 1,322.20 -$91.76 million ($2.22) -6.90
AXIM Biotechnologies N/A N/A N/A ($0.01) -1.62

AXIM Biotechnologies has lower revenue, but higher earnings than Icosavax. Icosavax is trading at a lower price-to-earnings ratio than AXIM Biotechnologies, indicating that it is currently the more affordable of the two stocks.


This table compares Icosavax and AXIM Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Icosavax N/A -43.06% -39.53%
AXIM Biotechnologies N/A N/A N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Icosavax and AXIM Biotechnologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Icosavax 0 2 1 0 2.33
AXIM Biotechnologies 0 0 0 0 N/A

Icosavax presently has a consensus price target of $26.50, suggesting a potential upside of 73.09%. Given Icosavax’s higher probable upside, equities analysts clearly believe Icosavax is more favorable than AXIM Biotechnologies.

Institutional and Insider Ownership

92.6% of Icosavax shares are held by institutional investors. 30.6% of Icosavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


Icosavax beats AXIM Biotechnologies on 5 of the 9 factors compared between the two stocks.

About Icosavax

(Get Free Report)

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

About AXIM Biotechnologies

(Get Free Report)

AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.

Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with's FREE daily email newsletter.